Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

BACKGROUND: Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We aimed to evaluate the use of ipilimumab and anti-PD...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Wong, Jeffrey Sum Lung, Kwok, Gerry Gin Wai, Tang, Vikki, Li, Bryan Cho Wing, Leung, Roland, Chiu, Joanne, Ma, Ka Wing, She, Wong Hoi, Tsang, Josephine, Lo, Chung Mau, Cheung, Tan To, Yau, Thomas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2021
Konular:
Clinical/Translational Cancer Immunotherapy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7875295/
https://ncbi.nlm.nih.gov/pubmed/33563773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001945
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller